Assembly Biosciences (ASMB) vs Evotec (EVO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Assembly Biosciences (ASMB) has outperformed Evotec (EVO) over the past year, losing 42.4% versus a loss of 55.6%. Over five years, ASMB leads with a -21.3% price change compared with -94.4% for EVO. Evotec is the larger company by market cap ($469.1 million vs $454.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | EVO |
|---|---|---|
| Share price | $22.19 | $1.32 |
| Market cap | $454.39M | $469.11M |
| 1-day change | -1.38% | -8.97% |
| YTD return | -34.75% | -57.14% |
| 1-year return | -42.36% | -55.56% |
| 5-year return | -21.31% | -94.44% |
| P/E ratio (TTM) | 29.59 | — |
| EPS (TTM) | $0.75 | $-0.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.30M | — |
| Revenue growth (YoY) | +153.52% | — |
| Net income (latest FY) | $-6.12M | — |
| Operating margin | -16.76% | — |
| Net margin | -8.47% | — |
| 52-week high | $39.65 | $3.87 |
| 52-week low | $19.20 | $1.32 |
| Distance from 52-week high | -44.04% | -65.89% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +130.73% | +237.12% |
| Average volume | 309.38K | 109.16K |
| Shares outstanding | 20.48M | 355.39M |
| Employees | 73 | 4,379 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ASMB has outperformed EVO by 13.2 percentage points over the past year.
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,379 employees
ASMB vs EVO FAQ
Which is bigger, Assembly Biosciences or Evotec?
Evotec (EVO) is larger, with a market capitalization of $469.11M compared with $454.39M for Assembly Biosciences (ASMB).
Which stock has performed better over the past year, ASMB or EVO?
ASMB returned -42.36% over the past 12 months, compared with -55.56% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Evotec in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.